Zurcher Kantonalbank Zurich Cantonalbank Acquires 4,994 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 9.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 60,240 shares of the biotechnology company’s stock after purchasing an additional 4,994 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Exelixis were worth $1,445,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Alaska Permanent Fund Corp boosted its stake in shares of Exelixis by 1.5% in the 3rd quarter. Alaska Permanent Fund Corp now owns 40,855 shares of the biotechnology company’s stock valued at $893,000 after purchasing an additional 596 shares during the last quarter. Fifth Third Bancorp boosted its stake in Exelixis by 44.2% during the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 604 shares during the last quarter. Signaturefd LLC boosted its stake in Exelixis by 17.1% during the 3rd quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 668 shares during the last quarter. Treasurer of the State of North Carolina boosted its stake in Exelixis by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company’s stock worth $3,176,000 after acquiring an additional 738 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in Exelixis by 1.7% during the 3rd quarter. Victory Capital Management Inc. now owns 56,321 shares of the biotechnology company’s stock worth $1,231,000 after acquiring an additional 927 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Down 0.8 %

Shares of EXEL stock opened at $23.53 on Friday. The firm has a market cap of $6.94 billion, a PE ratio of 36.77, a P/E/G ratio of 0.62 and a beta of 0.54. Exelixis, Inc. has a 12 month low of $18.08 and a 12 month high of $24.34. The company’s fifty day simple moving average is $22.73 and its 200-day simple moving average is $22.17.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. The business had revenue of $479.65 million for the quarter, compared to the consensus estimate of $481.23 million. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. On average, equities analysts predict that Exelixis, Inc. will post 1.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director David Edward Johnson bought 190,000 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were acquired at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the acquisition, the director now owns 1,100,730 shares in the company, valued at $22,785,111. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director David Edward Johnson acquired 190,000 shares of the firm’s stock in a transaction on Wednesday, February 21st. The shares were purchased at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the acquisition, the director now directly owns 1,100,730 shares in the company, valued at $22,785,111. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, EVP Patrick J. Haley sold 47,020 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the completion of the transaction, the executive vice president now owns 384,866 shares in the company, valued at $8,255,375.70. The disclosure for this sale can be found here. 2.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on EXEL shares. Barclays lowered shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective on the stock. in a research note on Thursday, April 11th. Stifel Nicolaus lifted their price objective on shares of Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Friday, February 2nd. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, March 18th. JMP Securities reaffirmed a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research note on Wednesday, April 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research note on Friday, January 26th. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $26.29.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.